专利检索 ap:("The U.S.A., as represented by the Secretary, Department of Health AND Human Services") AND inv:"Shirin Munir" 第 1 页

1.

发明公开
RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE 审中-公开

公开(公告)号：US20240197861A1

公开(公告)日：2024-06-20

申请号：US18555137

申请日：2022-04-27

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Ursula J. Buchholz , Shirin Munir , Cyril Le Nouen , Xueqiao Liu , Cindy Luongo , Peter L. Collins

IPC分类号： A61K39/215 , A61K39/00 , A61K39/155 , A61P31/14 , A61P37/04 , C07K14/005 , C12N15/86

CPC分类号： A61K39/215 , A61K39/155 , A61P31/14 , A61P37/04 , C07K14/005 , C12N15/86 , A61K2039/5256 , A61K2039/543 , A61K2039/55 , C12N2760/18622 , C12N2760/18634 , C12N2760/18644 , C12N2760/18671 , C12N2770/20022 , C12N2770/20034 , C12N2770/20071

摘要： Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing a recombinant Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike (S) protein as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the recombinant SARS-COV-2 S protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to SARS-COV-2 and HPIV3 in a subject.

2.

发明公开
USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION 审中-公开

公开(公告)号：US20240226118A1

公开(公告)日：2024-07-11

申请号：US18538065

申请日：2023-12-13

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Peter L. Collins , Matthias Lingemann , Shirin Munir

IPC分类号： A61K31/58 , A61K9/00 , A61P31/14

CPC分类号： A61K31/58 , A61K9/0043 , A61K9/0078 , A61P31/14

摘要： Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.

3.

发明申请
USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION 有权

公开(公告)号：US20220249518A1

公开(公告)日：2022-08-11

申请号：US17725331

申请日：2022-04-20

申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services

发明人： Peter L. Collins , Matthias Lingemann , Shirin Munir

IPC分类号： A61K31/58 , A61K9/00 , A61P31/14

摘要： Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.